M&A

News

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

News

Eli Lilly has agreed a $1.2bn takeover of Ventyx Bio and its clinical-stage drugs for inflammatory and cardiometabolic diseases.

News

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

R&D

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

News

Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.

News

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.